KALA BIO, Inc. — Director's Dealing 2017

Jul 21, 2017

SEC Form 3/A — Form 3/A

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19

Reporting Person: McDermott Charles Douglas (President and Chief Bus. Off., 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.68	2023-06-14	Common Stock (24000)		Direct
Stock Option (right to buy)	$2.30	2018-06-03	Common Stock (62056)		Direct

Footnotes

F1: This form amends a Form 3 previously filed for the Reporting Person on July 19, 2017 to correct the description of the vesting schedule of stock options reported herein.

F2: This option was granted on June 14, 2013, and vests as to 100% of the shares underlying the option: (A) immediately prior to the closing of a change of control with aggregate consideration of greater than $300,000,000 or (B) following the Issuer's initial public offering with a resulting market capitalization of over $300,000,000 following the date of the expiration of market stand-off agreements executed in connection with the Issuer's initial public offering. This option will expire without vesting if neither condition occurs prior to June 3, 2018.

F3: This option was granted on October 2, 2014, and vests as follows: either (A) upon a change of control with aggregate consideration (i) in excess of $400 million, with respect to 100% of the shares underlying the option, (ii) from $300 million to $400 million, with respect to 66.667% of the shares underlying the option or (iii) from $250 million to $300 million, with respect to 33.333% of the shares underlying the option or (B) following the Issuer's initial public offering with a resulting market capitalization following the expiration of market stand-off agreements executed in connection with such offering (i) in excess of $400 million, with respect to 100% of the shares underlying the option, (ii) from $300 million to $400 million, with respect to 66.667% of the shares underlying the option or (iii) from $250 million to $300 million, with respect to 33.333% of the shares underlying the option. This option will expire without vesting if neither condition occurs before June 3, 2018.